AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Oncology Today with Dr Neil Love
00:00
CAPItello-281 Trial Design
Karim Fizazi describes CAPItello-281 enrollment, PTEN IHC ≥90% cutoff, and randomized abiraterone±capivasertib design.
Play episode from 39:13
Transcript
